Kura Oncology Inc. is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of precision medicines for cancer treatment. It specializes in novel therapies that selectively target cancer cells, addressing areas with significant unmet medical needs such as HRAS mutant solid tumors, chronic myelomonocytic leukemia, MAPK pathway tumors, and acute leukemias. The company's pipeline features Tipifarnib, a farnesyl transferase inhibitor; KO-947, an ERK inhibitor; and KO-539, a Menin-MLL inhibitor, alongside approved products like Komzifti (ziftomenib) for specific leukemias. Kura Oncology Inc. advances precision oncology by developing targeted treatments that aim to improve patient outcomes in oncology. Founded in 2014 and headquartered in San Diego, California, it operates in the biopharmaceutical sector, contributing to innovative cancer care through its clinical-stage programs.